research-triangle
(3)
Cory Sanderson Is Trying to Make Carbon Removal Boring Enough to Scale
After years inside industrial gas systems, the Sustaera co-founder rebuilt direct air capture around a stubborn idea: climate hardware wins when the complicated parts disappear.
The Durham Investor That Treats Venture Capital Like a Clinical Program
Pappas Capital has spent three decades turning laboratory risk into investable milestones. Its edge is less about chasing crowded hubs than combining drug-development judgment, company-building work and patient capital from a base in Research Triangle Park.
Basking Biosciences, Inc.
Basking Biosciences is a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapy for acute ischemic stroke. Its lead candidate, BB-031, is a first-in-class RNA aptamer that inhibits von Willebrand Factor to break up clots quickly, paired with a companion reversal agent, BB-025, that can switch the drug's activity off in minutes if bleeding occurs. Spun out of research begun at Duke University and founded in 2019, the company is based in the Research Triangle of North Carolina and is advancing BB-031 through a Phase 2 RAISE trial.